MedTrace Logo

Psychological Traits, Sexuality and Quality of Life in Patients With Polycystic Ovary Syndrome

NCT03306459 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2017-10-20

No results posted yet for this study

Summary

A prospective assessment of psychological characteristics, quality of life and sexuality in naïve patients.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DIAGNOSTIC_TEST

SF-36 (Short Form Health Survey)

Symptom Checklist-90-Revision (SCL-90-R): self-report questionnaire of 90 items on a 5-point Likert scale clustered in 9 primary scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism). State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2): self-report questionnaire of 57-items on a 4-point scale distributed in different dimensions: State-Anger, Trait-Anger Expression Anger (in-out) and Anger Control (in-out) Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health. Female Sexual Function Index (FSFI) a 19-item self-report measure of female sexual function providing scores on 6 domains (desire, arousal, lubrication, orgasm, satisfaction, pain) as well as a total score.

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    lead OTHER

Principal Investigators

  • Camil Castelo-Branco, MD PhD · Hospital Clínic. University of Barcelona

Eligibility

Min Age
16 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-09
Primary Completion
2019-01-09
Completion
2020-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03306459 on ClinicalTrials.gov